News & Updates
Showing Infectious Diseases articles
Showing

Breath-holding may predict adverse outcomes in COVID-19 patients
A higher prediction score in breath-holding is associated with nearly a fivefold increased likelihood of respiratory failure in COVID-19 patients, as well as with greater severity of pulmonary deficits seen in chest imaging, a study has shown.

Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.

Which factors raise HCC risk in patients with cured HCV?
Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.

ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
A significant number of patients with infective endocarditis have been found to have antineutrophil cytoplasmic antibody (ANCA), which is associated with longer disease duration, more frequent purpura, and kidney involvement, results of a study has shown.

Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.

TB rates elevated after ART initiation in PLHIV
People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

High-flow oxygen does not reduce mortality in COVID-19 respiratory failure
The use of high-flow nasal cannula oxygen, as opposed to standard oxygen, in the first-line setting, did not reduce mortality rates in patients admitted to intensive care units (ICUs) for respiratory failure due to COVID-19, results of the SOHO-COVID trial showed.


